Vancouver, BC / ACCESSWIRE / July 02, 2014 / Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTC PINK: ATTBF) (CSE: ATT), a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced that Brazos Minshew, Chief Executive Officer of Samuel J. Brant, LLC and would like to issue the following correction.
In announcing the appointment of Brazos Minshew, the company stated…
“Founded in 2010, BioCell Labs is the holder of numerous patented and proprietary products, a Health Canada MMPR license and a nutraceutical production facility. As President of BioCell Labs, Brazos Minshew is tasked with consolidating Intellectual Properties, refining production strategies and creating distribution logistics through aggressive project management.”
The word APPLICATION was mistakenly omitted. Investors should not trade on any expectation or belief that Biocell Labs has an MMPR license.
The sentence should read … Founded in 2010, BioCell Labs is the holder of numerous patented and proprietary products, a Health Canada MMPR license APPLICATION and a nutraceutical production facility. As President of BioCell Labs, Brazos Minshew is tasked with consolidating Intellectual Properties, refining production strategies and creating distribution logistics through aggressive project management.
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.
ON BEHALF OF THE BOARD
Michael Withrow, President & CEO
For further information, contact the Company’s CEO, Michael Withrow at (778) 896-6536 or at firstname.lastname@example.org.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.